Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ENZN Stock Summary
In the News
7 Undervalued Biotech Stocks to Buy Before They Boom
You'll often hear people say that bear markets are great for finding bargains, and that's true. With the exception of energy, every major sector is in the red for the year.
Enzon Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. Feinstein, Enzon's CFO, to Assume Position of CEO and Remain CFO
CRANFORD, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTC:ENZN) announced today that Andrew Rackear has communicated to the Board his intent to retire from his role as the Company's Chief Executive Officer effective February 26, 2021. Andy joined Enzon in 2010 as Vice-President and General Counsel and has served as CEO since 2016. Upon Andy's retirement, Richard L. Feinstein, Enzon's Chief Financial Officer, will also assume the role of Chief Executive Officer and Secretary, as well as remain the Company's Chief Financial Officer. Mr. Rackear will be available as a consultant to the Company following his retirement, as may be needed.
ENZN Financial details
ENZN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0.01 | 0 | 0 | |
Net income per share | -0.02 | -0.03 | -0.01 | 0 | 0.02 | |
Operating cash flow per share | 0.16 | -0.01 | -0.01 | -0.01 | 0.02 | |
Free cash flow per share | 0.16 | -0.01 | -0.01 | -0.01 | 0.02 | |
Cash per share | 0.12 | 0.94 | 0.64 | 0.63 | 0.63 | |
Book value per share | 0.14 | 0.94 | 0.64 | 0.62 | 0.62 | |
Tangible book value per share | 0.14 | 0.94 | 0.64 | 0.62 | 0.62 | |
Share holders equity per share | 0.14 | 0.94 | 0.64 | 0.62 | 0.62 | |
Interest debt per share | 0 | 0 | 0 | -0.01 | 0 | |
Market cap | 9.11M | 12.69M | 25.42M | 18.31M | 6.94M | |
Enterprise value | 3.66M | -35.45M | -22.22M | -28.68M | -40.07M | |
P/E ratio | -9.3 | -9.68 | -54.2 | -98.41 | 5.06 | |
Price to sales ratio | 44 | 244.1 | 36.26 | 704.04 | 0 | |
POCF ratio | 1.32 | -33.4 | -50.74 | -27.78 | 5.32 | |
PFCF ratio | 1.32 | -33.4 | -50.74 | -27.78 | 5.32 | |
P/B Ratio | 1.5 | 0.27 | 0.54 | 0.4 | 0.15 | |
PTB ratio | 1.5 | 0.27 | 0.54 | 0.4 | 0.15 | |
EV to sales | 17.69 | -681.71 | -31.7 | -1.1K | 0 | |
Enterprise value over EBITDA | -3.76 | 27.16 | 47.38 | 27.79 | 38.38 | |
EV to operating cash flow | 0.53 | 93.29 | 44.36 | 43.52 | -30.7 | |
EV to free cash flow | 0.53 | 93.29 | 44.36 | 43.52 | -30.7 | |
Earnings yield | -0.11 | -0.1 | -0.02 | -0.01 | 0.2 | |
Free cash flow yield | 0.76 | -0.03 | -0.02 | -0.04 | 0.19 | |
Debt to equity | 0 | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | 5.6 | 36.89 | 101.58 | 45.53 | 45.03 | |
Current ratio | 14.17 | 117.07 | 118.5 | 27.89 | 27.62 | |
Interest coverage | 0 | 0 | 0 | 1.6 | 0 | |
Income quality | -7.05 | 0.29 | 1.07 | 3.54 | 0.95 | |
Dividend Yield | 0.87 | 0.04 | 0.08 | 0.07 | 0.18 | |
Payout ratio | -8.13 | -0.35 | -4.31 | -6.85 | 0.93 | |
Sales general and administrative to revenue | 5.7 | 26.1 | 1.67 | 40.69 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0.26 | 0.73 | 0.3 | 0.19 | 0.51 | |
ROIC | -0.16 | -0.03 | -0.01 | -0.01 | -0.03 | |
Return on tangible assets | -0.15 | -0.03 | -0.01 | 0 | 0.03 | |
Graham Net | 0.12 | 0.93 | 0.64 | 0.61 | 0.61 | |
Working capital | 5.57M | 47.82M | 47.35M | 45.69M | 45.63M | |
Tangible asset value | 6.06M | 47.82M | 47.35M | 45.89M | 45.99M | |
Net current asset value | 5.57M | 47.82M | 47.35M | 45.69M | 45.63M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 4.23M | 258K | 29.5K | 14K | 0 | |
Average payables | 381.5K | 313K | 316.5K | 331K | 331K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 855.19 | 217.6 | 14.58 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0.43 | 1.68 | 25.04 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.16 | -0.03 | -0.01 | 0 | 0.03 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | 0 | 0 | 0 | 0 | 0.01 | |
Operating cash flow per share | 0 | 0 | 0 | 0.01 | 0.01 | |
Free cash flow per share | 0 | 0 | 0 | 0.01 | 0.01 | |
Cash per share | 0.63 | 0.62 | 0.62 | 0.63 | 0.63 | |
Book value per share | 0.62 | 0.62 | 0.62 | 0.03 | 0.62 | |
Tangible book value per share | 0.62 | 0.62 | 0.62 | 0.03 | 0.62 | |
Share holders equity per share | 0.62 | 0.62 | 0.62 | 0.03 | 0.62 | |
Interest debt per share | 0 | -0.01 | 0 | 0 | 0 | |
Market cap | 18.31M | 19.3M | 14.84M | 10.89M | 6.94M | |
Enterprise value | -28.68M | -26.58M | -31.29M | -35.67M | -40.07M | |
P/E ratio | 13.74 | 24.49 | 20.28 | 8.48 | 2.58 | |
Price to sales ratio | 704.04 | 0 | 0 | 0 | 0 | |
POCF ratio | 140.81 | 113.51 | 58.44 | 25.55 | 15.26 | |
PFCF ratio | 140.81 | 113.51 | 58.44 | 25.55 | 15.26 | |
P/B Ratio | 0.4 | 0.42 | 0.32 | 4.33 | 0.15 | |
PTB ratio | 0.4 | 0.42 | 0.32 | 4.33 | 0.15 | |
EV to sales | -1.1K | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 135.91 | 93.27 | 98.39 | 158.54 | 185.51 | |
EV to operating cash flow | -220.59 | -156.36 | -123.18 | -83.74 | -88.06 | |
EV to free cash flow | -220.59 | -156.36 | -123.18 | -83.74 | -88.06 | |
Earnings yield | 0.02 | 0.01 | 0.01 | 0.03 | 0.1 | |
Free cash flow yield | 0.01 | 0.01 | 0.02 | 0.04 | 0.07 | |
Debt to equity | 0 | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | 222.66 | 160.97 | 145.07 | 206.92 | 217.65 | |
Current ratio | 27.89 | 113.38 | 115.63 | 115.48 | 27.62 | |
Interest coverage | 0.61 | 0.64 | 0 | 0 | 0 | |
Income quality | 0.39 | 0.86 | 1.39 | 1.33 | 0.68 | |
Dividend Yield | 0 | 0.07 | 0 | 0 | 0 | |
Payout ratio | 0 | 6.47 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 9.12 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0.25 | 0.19 | 0.19 | 0.06 | 0.36 | |
ROIC | -0.01 | -0.01 | -0.01 | -0.07 | -0.01 | |
Return on tangible assets | 0.01 | 0 | 0 | 0.01 | 0.01 | |
Graham Net | 0.61 | 0.61 | 0.62 | 0.03 | 0.61 | |
Working capital | 45.69M | 45.85M | 46.08M | 46.48M | 45.63M | |
Tangible asset value | 45.89M | 46.09M | 46.27M | 2.52M | 45.99M | |
Net current asset value | 45.69M | 45.85M | 46.08M | 2.4M | 45.63M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 331K | 331K | 331K | 334K | 334K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.01 | 0 | 0 | 0.13 | 0.01 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
ENZN Frequently Asked Questions
What is Enzon Pharmaceuticals, Inc. stock symbol ?
Enzon Pharmaceuticals, Inc. is a US stock , located in Cranford of Nj and trading under the symbol ENZN
What is Enzon Pharmaceuticals, Inc. stock quote today ?
Enzon Pharmaceuticals, Inc. stock price is $0.0945 today.
Is Enzon Pharmaceuticals, Inc. stock public?
Yes, Enzon Pharmaceuticals, Inc. is a publicly traded company.